DR5 LIGAND DRUG CONJUGATES

Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker un...

Full description

Saved in:
Bibliographic Details
Main Authors OHTSUKA, TOSHIAKI, ICHIKAWA, KIMIHISA, YADA, AYUMI
Format Patent
LanguageEnglish
French
Published 31.10.2013
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody. La présente invention concerne des conjugués ligand-médicament possédant un fragment de liaison DR5 fixé par le biais de groupes de liaison et/ou d'espaceurs à un agent thérapeutique, qui sont efficaces dans le traitement de divers cancers.
Bibliography:Application Number: CA20132869846